3SBio Inc. (01530.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.4x

Market Cap

HKD 39.35B

MomentumView details →

1D Return

−0.31%

YTD Return

−32.84%

RSI (14)

41.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.4x

Market Cap

HKD 39.35B

RSI (14)

41.5

MomentumView details →

1D Return

−0.31%

YTD Return

−32.84%

ProfitabilityView details →

Gross Margin

89.74%

Net Margin

39.49%

EBITDA Margin

52.42%

ROE (TTM)

38.57%

ROA (TTM)

29.84%

Asset Turnover

0.75x

GrowthView details →

Revenue YoY

+68.23%

EPS YoY

+194.52%

FCF YoY

+228.90%

Revenue CAGR 3Y

+37.15%

EPS CAGR 3Y

+63.83%

EBITDA YoY

+175.35%

EarningsView details →

EPS (Actual)

HKD 0.51

EPS Surprise

−31.26%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−31.26%

Rev Surprise

−3.41%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

6.06x

Quick Ratio

5.75x

Div Yield

1.54%

Div Rate

HKD 0.25

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

26.88B

Net Income (TTM)

10.61B

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

3SBio Inc. announced its interim results for the six months ended June 2026, with net profit of RMB 1.147 billion, down 15.6% year-on-year.15d ago

Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.45d ago

Similar companies

三生国健688336.SH Shanghai Henlius Biotech, Inc.02696.HK IMBdx461030.KQ Oncocross Co., Ltd.382150.KQ 君实生物-U688180.SH Alnylam Pharmaceuticals, Inc.ALNY Find similar companies →

Latest newsMore news →

3SBio Inc. announced its interim results for the six months ended June 2026, with net profit of RMB 1.147 billion, down 15.6% year-on-year.15d ago Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.45d ago